New Board of Directors for machineMD

In order to accompany machineMD into an even more successful future, the company has appointed a new Board of Directors. In addition to co-founder and Medical Director Prof. Dr. Mathias Abegg, life science and start-up specialist Carsten Laue and the investor and industry expert Reto Senn have joined the Board of Directors. The board is chaired by Carsten Laue. The new team brings a lot of experience and know-how with launching innovations and an extensive network that is very valuable for machineMD.  


Carsten Laue is passionate about innovation, strategy development and implementation in the life sciences field and has extensive start-up and Board of Director experience. The Swiss innovation promotion agency Innosuisse nominated Carsten as General Life Science Expert for the organization. He also occupies the position as Head of Funding and Community Platform at the Swiss Biotech Association. As CEO and executive Board Member Carsten led the development of an ophthalmology product (intraocular adjustable lens) to CE-mark, market launch and subsequent sale of the company to Carl-Zeiss Meditec, a top 4 market player in the ophthalmology space. Carsten worked at the IMD Business School in Lausanne, in venture capital and led a drug development and clinical research organization. He holds a PhD from EPFL, Switzerland and Master’s degree in Chemistry from the Technical University Darmstadt, Germany. 

Reto Senn is an investor and industry expert with 30 years' experience in pharmaceuticals, medical devices and ophthalmology. He started his career with Novartis in Basel, and then lived 21 years in Asia where he held various senior management positions including Divisional Head for North Asia of B.Braun’s Hospital Care Unit and CEO at Zuellig Pharma in Indonesia and Vietnam. Most recently he was a Member of the Executive Board at Vision Ophthalmology Group, a pan-European distributor of ophthalmology products, headquartered in Frankfurt. He currently acts as CEO of Nucleoptis International AG and is co-owner and Chairman of Von Hoff AG, a leading distributor for ophthalmological diagnostics in Switzerland, based in Zurich. Reto Senn is well connected and brings with him a wealth of expertise in accessing new markets, assessing distributors as well as transacting acquisitions and divestitures. He holds a master degree in Business Administration and Economics from the University of St.Gallen as well as a master degree in Higher Education from the University of Zurich. 

Mathias Abegg studied medicine in Zurich and Lausanne. His first research area was basic brain research in electrophysiology at the Brain Research Institute in Zurich, where he obtained his PhD. After residency training in ophthalmology in Zurich, Bern and Canada, he was awarded a combined clinical research fellowship in Vancouver, Canada. There he changed brain research methodology from in vitro mouse models to human eye tracking and human electrophysiology. Mathias Abegg is founder of the Eye Movement Laboratory, initiator of the BISS study and was head of the orthoptic department of the University Hospital in Bern for 12 years. He is co-founder of machineMD, Onovis AG, ebovis and co-organizer of the annual international strabismus conference in Zermatt. His clinical focus areas are pediatric ophthalmology, strabismus surgery and neuro-ophthalmology.

The new Board of Directors of machineMD
Carsten Laue (Chair of the Board), Reto Senn, Prof. Dr. Mathias Abegg